{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=75", "query": { "condition": "Relapsed/Refractory", "page": 75 }, "page_size": 10 }, "pagination": { "page": 75, "page_size": 10, "total_count": 3666, "total_pages": 367, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=76&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=74&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-14T20:27:58.206Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00515138", "title": "A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Lymphoma, B-Cell" ], "interventions": [ { "name": "Rituximab, Ifosfamide, Carboplatin, Etoposide, Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 7, "start_date": "2007-05", "completion_date": "2011-11", "has_results": false, "last_update_posted_date": "2012-04-12", "last_synced_at": "2026-11-14T20:27:58.206Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00515138" }, { "nct_id": "NCT04029688", "title": "A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia (AML)", "Acute Lymphoblastic Leukemia (ALL)", "Neuroblastoma", "Solid Tumors" ], "interventions": [ { "name": "Idasanutlin", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Intrathecal Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "0 Years to 30 Years" }, "enrollment_count": 38, "start_date": "2020-01-27", "completion_date": "2024-05-06", "has_results": true, "last_update_posted_date": "2024-12-20", "last_synced_at": "2026-11-14T20:27:58.206Z", "location_count": 5, "location_summary": "Little Rock, Arkansas • Palo Alto, California • Orlando, Florida + 2 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Palo Alto", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04029688" }, { "nct_id": "NCT03275103", "title": "Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Cevostamab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 355, "start_date": "2017-09-19", "completion_date": "2026-01-07", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-11-14T20:27:58.206Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03275103" }, { "nct_id": "NCT05317403", "title": "Venetoclax to Augment Epigenetic Modification and Chemotherapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia, in Relapse", "Acute Myeloid Leukemia Refractory" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Azacitadine", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "25 Years", "sex": "ALL", "summary": "1 Year to 25 Years" }, "enrollment_count": 40, "start_date": "2023-03-31", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-01-12", "last_synced_at": "2026-11-14T20:27:58.206Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05317403" }, { "nct_id": "NCT05182073", "title": "FT576 in Subjects With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Myeloma" ], "interventions": [ { "name": "FT576 (Allogenic CAR NK cells with BCMA expression)", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2021-11-10", "completion_date": "2024-10-18", "has_results": false, "last_update_posted_date": "2025-12-12", "last_synced_at": "2026-11-14T20:27:58.206Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Duarte, California • Denver, Colorado + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Newark", "state": "Delaware" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05182073" }, { "nct_id": "NCT02004522", "title": "A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Duvelisib", "type": "DRUG" }, { "name": "Ofatumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SecuraBio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 319, "start_date": "2013-11", "completion_date": "2021-06", "has_results": true, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-11-14T20:27:58.206Z", "location_count": 37, "location_summary": "La Jolla, California • Denver, Colorado • Altamonte Springs, Florida + 32 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Altamonte Springs", "state": "Florida" }, { "city": "Bonita Springs", "state": "Florida" }, { "city": "Bradenton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02004522" }, { "nct_id": "NCT00898612", "title": "Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lymphoma" ], "interventions": [], "intervention_types": [], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 0, "start_date": "2008-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-03-10", "last_synced_at": "2026-11-14T20:27:58.206Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00898612" }, { "nct_id": "NCT01938001", "title": "Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 358, "start_date": "2013-11-21", "completion_date": "2022-01-26", "has_results": true, "last_update_posted_date": "2023-02-22", "last_synced_at": "2026-11-14T20:27:58.206Z", "location_count": 35, "location_summary": "Mobile, Alabama • Glendale, Arizona • Escondido, California + 31 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Escondido", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "La Verne", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01938001" }, { "nct_id": "NCT01186328", "title": "EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoblastic Leukemia, Acute", "Lymphoblastic Leukemia, Acute, Childhood", "Leukemia, Lymphoblastic, Acute, T Cell", "Leukemia, Lymphoblastic, Acute" ], "interventions": [ { "name": "EZN-3042", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "PEG-asparaginase", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Therapeutic Advances in Childhood Leukemia Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 6, "start_date": "2010-08-24", "completion_date": "2012-01-10", "has_results": true, "last_update_posted_date": "2024-02-01", "last_synced_at": "2026-11-14T20:27:58.206Z", "location_count": 6, "location_summary": "Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01186328" }, { "nct_id": "NCT03761095", "title": "A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leiomyosarcoma" ], "interventions": [ { "name": "Unesbulin", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PTC Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2019-03-13", "completion_date": "2024-02-05", "has_results": false, "last_update_posted_date": "2024-03-15", "last_synced_at": "2026-11-14T20:27:58.206Z", "location_count": 4, "location_summary": "Jacksonville, Florida • Baltimore, Maryland • St Louis, Missouri + 1 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03761095" } ] }